Statement of Organization, Functions, and Delegations of Authority, 66284-66285 [2016-23212]
Download as PDF
<![CDATA[
asabaliauskas on DSK3SPTVN1PROD with NOTICES
66284
Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices
related adverse events, contaminated
medical products and devices, and
adverse drug events; (7) communicates
the results of response activities with
Federal and state agencies, healthcare
providers, and the public, with
recommendations to prevent similar
adverse events in the future; and (8)
provides leadership and expert
consultation, guidance, and technical
support to and collaborates with other
CDC CIOs and divisions, other HHS
Operating Divisions, and extramural
domestic partners, on the epidemiology,
prevention, and control of HAI, AR, and
related adverse events; (9) implements
state activities to prevent HAI and AR
across healthcare; and (10) leads CDC
activities to promote antimicrobial
stewardship in all healthcare settings.
Surveillance Branch (CVLDD). (1)
Monitors and evaluates on the national
level the extent, distribution, and
impact of HAI, antimicrobial use and
resistance, adverse drug events,
healthcare worker safety events, and
adherence to clinical processes and
intervention programs designed to
prevent or control adverse exposures or
outcomes in healthcare; (2) provides
services, including leadership,
consultation, and analysis support, for
statistical methods and analysis to
investigators in the branch, division,
and other organizations responsible for
surveillance, research studies, and
prevention and control of HAI and other
healthcare-associated adverse events; (3)
works with the Centers for Medicare
and Medicaid Services and other
partners to develop new metrics and
support maintenance of National
Quality Forum-approved metrics; (4)
collaborates with public and private
sector partners to further standardize,
integrate, and streamline systems by
which healthcare organizations collect,
manage, analyze, report, and respond to
data on clinical guideline adherence,
HAI, including transmission of multidrug resistant organisms, and other HAI;
(5) coordinates, further develops,
enables wider use, and maintains NHSN
to obtain scientifically valid clinical
performance indices that promote
healthcare quality and value at the
facility, state, and national levels; (6)
develops and implements new NHSN
modules and provides enrollment and
user support for NHSN; (7) improves
surveillance systems by utilizing new
technology; (8) generates and provides
NHSN surveillance reports and
analyses, which include collaborative
analytic projects with partners; and (9)
leads CDC’s national adverse drug
events surveillance activities and seeks
to translate population-based
VerDate Sep<11>2014
17:08 Sep 26, 2016
Jkt 238001
surveillance data into evidence-based
policies and targeted, innovative and
collaborative interventions.
Immunization Safety Office (CVLDE).
Assesses the safety of new and currently
available vaccines received by children,
adolescents and adults using a variety of
strategies: (1) Conducts ongoing
surveillance for the timely detection of
possible adverse events following
immunization (AEFI) in collaboration
with the Food and Drug Administration
(FDA), through coordination and
management of the Vaccine Adverse
Event Reporting System, the national
reporting system that acts as an earlywarning system to detect health
conditions that may be associated with
immunization; (2) coordinates, further
develops, maintains and directs
activities of the Vaccine Safety Datalink
(VSD), a collaborative effort with
integrated healthcare organizations, to
conduct surveillance and investigate
possible AEFI to assess causality and
determine risk factors; (3) conducts
epidemiologic research on causality of
AEFI using the VSD and other data
sources, and provides national estimates
of incidence of AEFI and background
rates of health conditions; (4) leads the
nation in developing biostatistical
methods for research of AEFI using large
linked databases and other data sources,
and shares methods for use by other
Agencies and public and private
entities; (5) conducts clinical research to
identify causes of adverse events after
immunization, specific populations
susceptible to specific adverse events,
and prevention strategies through the
Clinical Immunization Safety
Assessment network, a national network
of medical research centers, and other
efforts; (6) applies findings from
epidemiologic and clinical studies to
develop strategies for prevention of
AEFI; (7) provides global consultation
and leadership for the development,
use, and interpretation of vaccine safety
surveillance systems, and for the
development of shared definitions of
specific health outcomes through
participation in the Brighton
Collaboration and other international
organizations; (8) provides data for
action to HHS, the Advisory Committee
on Immunization Practices, the FDA’s
Vaccine and Related Biological Products
Advisory Committee, Health Resources
and Services Administration’s Advisory
Commission on Childhood Vaccines,
and collaborators around the globe
including the WHO Global Advisory
Committee on Vaccine Safety; and (9)
provides timely, accurate
communication and education to
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
partners and the public on vaccine
safety concerns.
Epidemiology Research and
Innovations Branch (CVLDG). (1)
Identifies and evaluates the efficacy of
interventions to prevent HAI and related
adverse events or medical errors across
the spectrum of healthcare delivery sites
including acute and long-term inpatient
care, dialysis, and ambulatory settings;
(2) identifies gaps in HAI-related
knowledge, and conducts prevention
research through the Prevention
Epicenters cooperative agreements
program and Safety and Healthcare
Epidemiology Prevention Research
Development research contracts; (3)
conducts and supports research and
evaluates impact of public health
practices to prevent HAI, antimicrobial
resistance, and related adverse events;
(4) improves methods and enables wider
use of clinical performance
measurements by healthcare facilities
and public health entities for specific
interventions and prevention strategies
designed to safeguard patients and
healthcare workers from risk exposures
and adverse outcomes through
collaborations with extramural partners;
(5) conducts applied research to identify
and develop innovative methods to
detect and monitor HAI and
antimicrobial resistance; (6) conducts
special studies to identify key risk
factors for and provides national
estimates of targeted, healthcareassociated adverse events, antimicrobial
use and resistance patterns, and the
extent to which prevention and control
safeguards are in use to protect at-risk
patients across the spectrum of
healthcare delivery sites; (7) develops
new ways to assess the impact of HAI
prevention programs; (8) conducts
analysis of the return on investment and
costs related to prevention efforts and
impact of HAI prevention programs; and
(9) works with the Emerging Infections
Program (EIP) and other partners to
identify emerging issues.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2016–23213 Filed 9–26–16; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
E:\FR\FM\27SEN1.SGM
27SEN1
66285
Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 81 FR 54091–54094,
dated August 15, 2016) is amended to
reflect the reorganization of the Office of
the Director, National Center for
Emerging and Zoonotic Infectious
Diseases, Office of Infectious Diseases,
Centers for Disease Control and
Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Insert item (10) ensures compliance
with and manages the infectious
diseases Clinical Laboratory
Improvement Amendments (CLIA) unit
within the Office of Infectious Diseases
(CV), and renumber remaining items
accordingly.
Delete item (5) ensures scientific
quality and ethical and regulatory
compliance of center activities within
the National Center for Emerging and
Zoonotic Infectious Diseases (CVL),
Office of the Director (CVL1), and
renumber remaining items accordingly.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2016–23212 Filed 9–26–16; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request Proposed
Projects:
Title: Voluntary Acknowledgement of
Paternity and Required Data Elements
for Paternity Establishment Affidavits.
OMB No.: 0970–0171.
Description: Section 466(a)(5)(C) of
the Social Security Act requires States
to enact laws ensuring a simple civil
process for voluntarily acknowledging
paternity via an affidavit. The
development and use of an affidavit for
the voluntary acknowledgment of
paternity would include the minimum
requirements of the affidavit specified
by the Secretary under section 452(a)(7)
and give full faith and credit to such an
affidavit signed in any other State
according to its procedures. The State
must provide that, before a mother and
putative father can sign a voluntary
acknowledgement of paternity, the
mother and putative father must be
given notice, orally and in writing of the
alternatives to, the legal consequences
of, and the rights (including any rights,
if one parent is a minor, due to minority
status) and responsibilities of
acknowledging paternity. The affidavits
will be used by hospitals, birth record
agencies, and other entities participating
in the voluntary paternity establishment
program to collect information from the
parents of nonmarital children.
Respondents: The parents of
nonmarital children and State and
Tribal IV–D agencies, hospitals, birth
record agencies and other entities
participating in the voluntary paternity
establishment program.
ANNUAL BURDEN ESTIMATES
Number of
respondents/
partner
Instrument
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Training ............................................................................................................
Paternity Acknowledgment Process ................................................................
Data Elements .................................................................................................
Ordering Brochures .........................................................................................
Estimated Total Annual Burden
Hours: 782,003.
In compliance with the requirements
of the Paperwork Reduction Act of 1995
(Pub. L. 104–13, 44 U.S.C. Chap 35)
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 330 C Street SW.,
Washington DC 20201. Attn: ACF
Reports Clearance Officer. Email
address: infocollection@acf.hhs.gov. All
requests should be identified by the title
of the information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
VerDate Sep<11>2014
17:08 Sep 26, 2016
Jkt 238001
130,330
2,606,596
54
2,606,596
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2016–23274 Filed 9–26–16; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the 2018 Physical Activity
Guidelines Advisory Committee
Office of Disease Prevention
and Health Promotion, Office of the
AGENCY:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Number of
responses per
respondent/
partner
1
1
1
1
Average
burden hours
per response
1
0.17
1
.08
Total burden
hours
130,300
443,121
54
208,528
Assistant Secretary for Health, Office of
the Secretary, U.S. Department of Health
and Human Services.
ACTION: Notice.
As stipulated by the Federal
Advisory Committee Act (FACA), the
U.S. Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting of the 2018 Physical
Activity Guidelines Advisory
Committee (2018 PAGAC or Committee)
will be held. This meeting will be open
to the public.
DATES: The meeting will be held on
October 27, 2016, from 2:15 p.m. E.D.T.
to 5 p.m. E.D.T. and on October 28,
2016, from 8:00 a.m. E.D.T. to 3:30 p.m.
E.D.T.
ADDRESSES: The meeting will be
accessible by webcast on the Internet or
by attendance in-person. For in-person
participants, the meeting will take place
in the National Institutes of Health
(NIH) Masur Auditorium, NIH Clinical
Center, Building 10. The facility is
SUMMARY:
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 81, Number 187 (Tuesday, September 27, 2016)]
[Notices]
[Pages 66284-66285]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23212]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of
[[Page 66285]]
Organization, Functions, and Delegations of Authority of the Department
of Health and Human Services (45 FR 67772-76, dated October 14, 1980,
and corrected at 45 FR 69296, October 20, 1980, as amended most
recently at 81 FR 54091-54094, dated August 15, 2016) is amended to
reflect the reorganization of the Office of the Director, National
Center for Emerging and Zoonotic Infectious Diseases, Office of
Infectious Diseases, Centers for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
Insert item (10) ensures compliance with and manages the infectious
diseases Clinical Laboratory Improvement Amendments (CLIA) unit within
the Office of Infectious Diseases (CV), and renumber remaining items
accordingly.
Delete item (5) ensures scientific quality and ethical and
regulatory compliance of center activities within the National Center
for Emerging and Zoonotic Infectious Diseases (CVL), Office of the
Director (CVL1), and renumber remaining items accordingly.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2016-23212 Filed 9-26-16; 8:45 am]
BILLING CODE 4160-18-P
